Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Hello! And it’s Meghana again. Today, we discuss how Biogen’s missed the mark with Leqembi, but how it’s also not exactly a surprise. We see a new startup emerge that aims to compete with Vertex Pharmaceuticals, and learn of Phase 1 results for Replicate’s srRNA rabies vaccine.
A startup aims to compete with Vertex in pain
A new startup, Latigo Biotherapeutics, has launched with $135 million and the intention to compete with Vertex Pharmaceuticals. The company, which was incubated by the Los Angeles-area venture firm Westlake Village BioPartners, is in the midst a Phase 1 trial for a non-opioid pain medicine called LTG-001. It’s an oral drug meant to silence pain-signaling neurons by blocking a sodium channel called NaV 1.8.
About the Author Reprints
To submit a correction request, please visit our Contact Us page.
STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect